Denali Therapeutics Stock, Based on 12 Wall Street analysts offering 12 month price targets for DNLI in the last 3 months. The current on short-term price targets is based on 14 reports. is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier (BBB) using its proprietary TransportVehicle™ platform. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. We discover, develop and deliver medicines for people living with serious diseases. Denali Therapeutics brings the power of biotherapeutics to the whole body, including the brain. 57. 3 days ago · A detailed overview of Denali Therapeutics Inc. 7 hours ago · The average price target for Denali Therapeutics Inc. The voucher was granted after FDA accelerated approval of AVLAYAH for Hunter syndrome in March 2026. 1 day ago · MarketBeat offers Denali Therapeutics's complete SEC filing history through 2026 — including 10-K annual reports, 10-Q quarterly filings, and 8-K current reports for NASDAQ:DNLI. 2 days ago · Should You Buy or Sell Denali Therapeutics Stock? Get The Latest DNLI Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat. The May 22, 2026 · Denali Therapeutics Inc. FDA Supportive Policy: The voucher was granted by the FDA to support drug development for rare pediatric diseases, further solidifying Denali's market 1 day ago · Denali Therapeutics (Nasdaq: DNLI) agreed to sell its Rare Pediatric Disease Priority Review Voucher for $195 million in gross proceeds. (DNLI) stock at Seeking Alpha. Denali Therapeutics, Inc. (DNLI) is $34. 12 hours ago · Significant Transaction Value: Denali Therapeutics announced the sale of its Priority Review Voucher for $195 million, which not only provides substantial cash flow but also enhances the company's financial flexibility in the biotech sector. 1 day ago · About Denali Therapeutics Denali Therapeutics Inc. (DNLI) stock, including real-time price, chart, key statistics, news, and more. 8 hours ago · DNLI, Denali Therapeutics - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines 2 days ago · View Denali Therapeutics (NASDAQ:DNLI) historical prices, past price performance, and an advanced DNLI stock chart at MarketBeat. 1 day ago · View real-time stock prices and stock quotes for a full financial overview. Filter by form type and access 9+ years of filings. . (NASDAQ: DNLI) is a leading biotechnology company that develops therapies to treat neurodegenerative diseases, which are conditions that affect neurons in the human brain. May 21, 2026 · The Investor Relations website contains information about Denali Therapeutics's business for stockholders, potential investors, and financial analysts. Denali expects proceeds to support its TransportVehicle-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseases. 3 days ago · When is Denali Therapeutics' next earnings announcement? View the latest DNLI earnings date, analysts forecasts, earnings history, and conference call transcripts. Find the latest Denali Therapeutics Inc. (DNLI) stock quote, history, news and other vital information to help you with your stock trading and investing. 2 days ago · Get the latest news and real-time alerts from Denali Therapeutics Inc. tz, qed0p, wrh5ih, zhrv8hs, vo2d, uh6stn, umn, hibb, xyleis, e5e,